Upfront Payment of 75.5 Billion KRW; Targeting the 14-Trillion KRW Market
SK Bioscience and Sanofi Partner to Develop Next-Generation Pneumococcal Vaccine
SK Bioscience is teaming up with global pharmaceutical company Sanofi to jointly develop a next-generation pneumococcal conjugate vaccine. The collaboration aims to penetrate the 14-trillion KRW…